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Increasing resistance to drugs represents a serious problem in treatment of 
infections with Helicobacter pylori, providing cause of frequent therapeutic failures. 
Present study aimed at analysis of changes in resistance of H. pylori to antibiotics in 
West Poland within the recent 15 years. 108 strains of H. pylori were analysed, iso-
lated from gastric mucosa of adult patients. Group 1 involved 66 strains isolated in 
years of 1998/1999. Group 2 comprised 42 isolates obtained in years of 2013/2014. 
Susceptibility to amoxicillin (AMX), clarithromycin (CL), tetracycline (TC) and 
metronidazole (MTZ) was determined by E-test (AB Biodisc). All strains on both 
studied groups were susceptible to AMX. In group 1 all strains proved to be suscep-
tible to TC, while 9% and 36% of tested strains were resistant to CL and MTZ, re-
spectively. By contrast, in group 2, 31% and 83% of strains were resistant to CL and 
MTZ, respectively. In parallel, 14% strains were found to be resistant to TC (accord-
ing to EUCAST interpretations). In West Poland, within recent 15 years a dramatic 
increase was noted in H. pylori strains resistant to metronidazole. In parallel, a sig-
nifi cant increase was noted in proportion of strains resistant to clarithromycin.
Keywords: Helicobacter pylori, antibiotic resistance, chronic gastritis, pep-
tic ulcer disease, treatment
Introduction
Helicobacter pylori represents one of the most widespread pathogenic bac-
terial species affecting humans. Infections with H. pylori are common, burden-
*Corresponding author; E-mail: szkaradkiewicza@poczta.onet.pl
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ing around 50% of world populations [1]. In north European populations about 
30% of adults are infected, whereas in south and east Europe the prevalence of 
H. pylori is often higher than 50%. The highest prevalence of H. pylori amount-
ing to 84.2% was reported in Portugal [2]. H. pylori represents an etiological 
factor of peptic ulcer disease, gastric mucosa-associated lymphoid tissue (MALT) 
lymphoma, chronic gastritis with intestinal metaplasia and of gastric adenocarci-
noma [3]. Triple therapy including proton-pump inhibitor, amoxicillin and 
clarithromycin or metronidazole was generally accepted as the fi rst-line therapy 
[4, 5]. However, the therapy proved to be ineffective in up to 30–40% of patients 
[6, 7]. An important predictor of the success of H. pylori eradication therapy is 
the antimicrobial susceptibility. In H. pylori manifestation of resistance to antibi-
otics varies geographically and undergoes dynamic alterations [8]. Therefore, 
several research institutions throughout the world monitor current drug resist-
ance in H. pylori. Present study aimed at analysis of changes in resistance of 
H. pylori to antibiotics in West Poland within the recent 15 years.
Materials and Methods
Bacterial isolates
Evaluation of drug susceptibility was performed on the total of 108 strains 
of H. pylori originating from adult patients from West Poland. All the strains 
were isolated from gastric mucosa before treatment. Group 1 involved 66 strains 
isolated in years of 1998/1999. Group 2 comprised 42 isolates obtained in years of 
2013/2014. Biopsies isolated from the prepyloric portion were immediately placed 
in a transport medium (Portagerm pylori; bioMerieux). The obtained biopsies 
were plated on Columbia agar supplemented with 7% of sheep blood and a set of 
antibiotics (H. pylori selective supplement Dent SR 147E; Oxoid). The incubation 
was performed in microaerophilic conditions (Generbag or Generbox microaer; 
bioMerieux) at the temperature of 37 °C for 4–7 days. For the drug susceptibility 
test a suspension of grown bacteria was used, in PBS, manifesting density 2 in 
McF scale. The cultured strains were identifi ed based on colony morphology, 
Gram staining and urease and catalase tests. All the research protocols were 
 reviewed and approved by the Ethics Committee of the Poznan University of 
Medical Sciences, Poland.
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Antimicrobial susceptibility testing
Susceptibility to amoxicillin (AMX), clarithromycin (CL), tetracycline 
(TC) and metronidazole (MTZ) was determined by E-test (AB Biodisc; Solna). 
A strip was placed on Columbia agar supplemented with 7% of sheep blood 
with pre-plated, examined strain of H. pylori. The incubation was performed in 
microaerophilic conditions (Generbag or Generbox microaer; bioMerieux) at the 
temperature of 37 °C for 3 days. Resistance breakpoints of H. pylori were used 
and interpreted according to CLSI (AMX – 0.5 mg/L, CL – 1 mg/L, TC – 4 
mg/L, MTZ – 8 mg/L) and according to EUCAST (AMX – 0.12 mg/L, CL – 0.5 
mg/L, TC – 1 mg/L, MTZ – 8 mg/L).
Statistical methods
Statistical analysis was performed using Fisher’s exact test. A p-value high-
er than 0.05 was considered non-signifi cant.
Results
All examined H. pylori strains in both groups were susceptible to amoxicil-
lin (AMX). Group 1 contained no strains resistant to tetracycline (TC), in turn 
the group comprised 9% of strains resistant to clarithromycin (CL) and 36% of 
strains resistant to metronidazole (MTZ). On the other hand, Group 2 contained 
31% of strains resistant to CL and 83% of strains resistant to MTZ. Resistance to 
TC on Group 2 depended on the applied criteria: according to EUCAST it in-
volved 14% but none after CLSI recommendations. In line with the currently 
binding criteria of EUCAST, a signifi cant increase in their content of strains re-
sistant to TC (p < 0.0001), CL (p = 0.0003) and MTZ (p < 0.0001) was detected 
between the two groups. The results obtained in both groups of studied strains are 
presented in Table I.
Discussion
In treatment of infections with H. pylori, the universal and still applied 
triple therapy is also defi ned as fi rst-line therapy [5]. At present several factors are 
known which may reduce effi cacy of the standard triple therapy: they include the 
high bacterial load, type of strain, high gastric acidity and increase in H. pylori 
resistance to antibiotics [9].
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In the conducted experiments none of the analysed strains manifested resist-
ance to AMX. Nevertheless, in recent decade effi cacy of eradication in H. pylori 
infection following the triple therapy was found to be reduced [10]. In such a context 
it remains diffi cult to interpret the demonstrated susceptibility of isolates to AMX in 
both studied groups. Possibly, the clinical resistance of H. pylori to AMX depends 
on bioaccessibility of the drug in gastric mucosa linked to its acidity [9]. Our results 
have been confi rmed by other European data, documenting the level of resistance to 
amoxicillin of 0–0.9% [11]. A high proportion of primary amoxicillin resistance 
(13.6–59%) was detected in Africa, Asia and South America [12–14].
In the studies presented above the proportion of strains resistant to clarithro-
mycin in West Poland was found to comprise at present 31% and it increased by 
22% within recent 15 years. In addition, recent data indicate that genotype stud-
ies (by PCR) allow for a markedly more frequent detection of resistance to 
clarithromycin than using phenotypic determination (by E-test) [15]. In Europe 
clarithromycin resistance manifests a variable level and in strains isolated from 
adult patients in 2008–2009 on averaged at 17.5%. The highest proportion of 
strains resistant to clarithromycin was detected in Greece (42%) and the lowest 
one in Holland (5.6%) [11, 16]. In Poland, resistance to clarithromycin was gradu-
ally increasing, amounting in 1998/1999 to 9% [17], in 2001–2009 already to 15.4–
28% [18–20]. In studies presented here we have demonstrated 31% resistance of 
H. pylori strains to clarithromycin, which might point to a continuous increase in 
resistance to the drug. The increase in resistance to clarithromycin was observed 
also in strains isolated from children, linked to the widespread application of 
macrolide antibiotics in paediatrics [19, 21, 22]. Therefore, clarithromycin should 
not be applied in treatment of H. pylori infections without earlier estimation of 
susceptibility to the drug.
Table I. Resistance of Helicobacter pylori to AMX, CL, TC and MTZ in Group 1 (years 1998/1999) 
and Group 2 (years 2013/2014) according to EUCAST breakpoints
Antibacterial drug
Percent of resistance in studied groups 
of H. pylori strains Level of signifi cance; 
pGroup 1
(1998/1999)
Group 2
(2013/2014)
AMX  0%  0% 1.0000
CL  9% 31% 0.0003*
TC  0% 14% <0.0001*
MTZ 36% 83% <0.0001*
*signifi cantly different between both groups.
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In the conducted studies a signifi cant increase was noted in proportion of 
strains resistant to TC (0% in Group 1 versus 14% in Group 2). However, the data 
were obtained using interpretation criteria of EUCAST. On the other hand, using 
criteria of CLSI, no strain in either of the two groups manifested resistance to TC. 
Using CLSI criteria, other authors [11, 23, 24] demonstrated in Europe persistence 
of low resistance to TC (0–2.6%). Since interpretation criteria of EUCAST related to 
resistance of H. pylori to TC may result in divergent results, as compared to those 
obtained in line with the earlier CLSI recommendations, the matter requires verifi ca-
tion.
In this study we have for the fi rst time demonstrated a dramatic increase in 
resistance to metronidazole (83%) among strains isolated in 2013/2014. A similarly 
high frequency (50–80%) of strains resistant to the chemotherapeutic agent was 
noted in developing countries [12]. Between 2000–2010 in various European coun-
tries 20–43.8% of strains were found to be resistant to metronidazole. The high-
est proportion of resistant strains was demonstrated in Italy (59.3%) and in coun-
tries of Central and Western Europe (>40%) [11, 25]. In Poland, in 1998/1999 
resistance to metronidazole was manifested by 36% strains [17] and the proportion 
systematically grew in subsequent years, including 41.7–58.5% in 2000–2004 [19, 
20], and up to 66.7% in certain southern regions of Poland in 2008–2011 [26]. It 
seems probable that the signifi cant increase in resistance to metronidazole in Poland 
refl ects a sequel of using the drug not only in treatment of gynaecological and 
dental diseases but also as a drug for eradication of parasitic infections [22].
Thus, in West Poland, within recent 15 years a dramatic increase was noted 
in H. pylori strains resistant to metronidazole as well as in percentage of strains 
resistant to clarithromycin. In parallel, the EUCAST criteria for interpretation of 
H. pylori resistance to tetracycline require verifi cation.
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